Author: KBD Admin

PALO ALTO, Calif. – January 8, 2026 – Frazier Life Sciences (FLS), a longstanding investment firm focused on innovative therapeutics, today announced the promotions of Joe Cabral, M.S., MBA, and Kevin Li, M.D., to Partner, and Jennifer Martin to Chief Financial Officer and Partner, further bolstering its leadership team. The company also announced several promotions across the organization strengthening the team’s financial expertise and positioning the company to drive strategic growth.

“On behalf of the entire partnership, we are proud to congratulate Joe, Kevin and Jennifer on their well-deserved promotions,” said Patrick Heron, Managing Partner at FLS. “Each of these individuals have made significant contributions to our firm and portfolio, and we look forward to their continued leadership as we work to build and support the next generation of innovative life sciences companies. We also extend our congratulations to the many other team members recently promoted, reflecting the depth of talent across FLS and our commitment to strengthening financial expertise and leadership throughout the organization.”

Joe Cabral joined FLS in 2021 and plays an instrumental role in the firm’s private investment and company creation strategies. He has co-led investments in Halda Therapeutics and several other private companies still in stealth-mode, in each case serving as member of the board. Joe has contributed to multiple other investments including NewAmsterdam Pharma and currently serves as a board observer for Alpha-9 Oncology and Hillstar Bio. Prior to FLS, Joe worked at Flagship Pioneering, Generate:Biomedicines, and Moderna. Joe holds a Master of Business Administration from the Ross School of Business at the University of Michigan, as well as a Master of Science in Genomics and a Bachelor of Science in Biology from the University of Connecticut.

Kevin Li, M.D., joined FLS in 2021 and has been a key contributor to investments in public and late-stage private companies for the Frazier Life Sciences Public Fund (FLSPF), including those in Scorpion Therapeutics, 35Pharma, and GondolaBio. Previously, Kevin was a resident physician in Internal Medicine at Stanford and a consultant at McKinsey & Company, where he focused on corporate strategy, growth, and M&A in the hospital services and pharmaceutical industries. He earned his M.D. from Stanford University and his Bachelor of Science from Yale University, graduating summa cum laude in Molecular Biophysics and Biochemistry.

Jennifer Martin joined FLS in 2015 and has deep experience across venture capital, private equity and hedge fund investment platforms. Her expertise spans accounting, financial reporting, and operational finance for complex fund structures. She began her career as an auditor at PwC, advising asset management clients on financial reporting, controls, and compliance matters, and later held senior finance leadership roles within the private fund industry, including serving as CFO of Red Mountain Capital Partners. Jennifer earned a Bachelor of Arts in Accounting from Western Washington University.

Additional promotions announced include:

• Dan Ontiveros, J.D., promoted to Chief Compliance Officer
• Angel Martin, Ph.D., promoted to Vice President
• Kiah Williams, M.D., promoted to Vice President
• Xinghuo Li, Ph.D., promoted to Senior Associate
• Shu Yeung, MBA, promoted to Vice President, Human Resources
• Chris Wyckoff promoted to Director of Finance
• Nolan Nunez promoted to Controller, Venture Funds
• Stacy Clark promoted to Director, Firm Administration
• Wendy Cihak promoted to Investor Relations Coordinator and Executive Assistant

About Frazier Life Sciences:

Frazier Life Sciences (FLS) invests globally in private and publicly traded companies that discover, develop, and commercialize innovative biopharmaceuticals. Since 2016, the firm has raised over $5.3 billion including venture funds focusing on company creation and private companies and long-only public funds focused on small and mid-cap public companies. Since 2010, FLS portfolio companies have achieved 76 FDA-approved therapeutics and completed more than 60 IPOs or strategic acquisitions.

FLS is headquartered in Palo Alto, CA, with offices in San Diego, Seattle, and Boston.

For more information about FLS, please visit frazierls.com and follow us on LinkedIn.

For media inquiries, please contact:
Frazier Life Sciences
Investor Relations
ir@frazierls.com

PALO ALTO, Calif. – May 1, 2025 – Frazier Life Sciences (FLS), a longstanding investment firm focused on innovative therapeutics, today announced the appointment of Gordon Empey as Chief Operating Officer (COO). Gordon, who brings more than 25 years of experience advising venture capital investors and life sciences companies, will continue in his roles as Partner and General Counsel alongside his new responsibilities as COO.

In his expanded role, Gordon will oversee FLS’ enterprise functions, including legal, investor relations, operations, compliance, human resources, and information technology, while working closely with the investment and finance teams to align business operations with the firm’s strategic goals.

“Gordon has played an important role in FLS’ strategic expansion, contributing to the development of our long-only public fund strategy and the launch of FLS Public Funds,” said Patrick Heron, Managing Partner at FLS. “His appointment is a natural progression from his impactful leadership as Partner and General Counsel, where he has helped position the firm for sustained success and growth. We are excited for him to take on this expanded role.”

Since joining FLS in 2017, Gordon has served as General Counsel and Partner on the Life Sciences team, supporting the firm’s continued growth through its venture funds, including Frazier Life Sciences IX, L.P. ($419M), Frazier Life Sciences X, L.P. ($617M), and Frazier Life Sciences XI, L.P. ($987M). In his role, he has led investment structuring efforts, supported company formation activities, and advised numerous life sciences venture firms and portfolio companies on corporate strategy and transactions. Gordon also played a key role in the formation and launch of the FLS-sponsored SPAC, Frazier Lifesciences Acquisition Corporation, where he served as Vice President and General Counsel.

“It has been a privilege to work alongside the entire Frazier Life Sciences team and to contribute to the firm’s evolution during a period of meaningful growth,” said Gordon Empey, COO, Partner and General Counsel at FLS. “I look forward to continuing to support the firm’s efforts to build transformative companies that can have a significant impact on patients’ lives.”

Prior to joining FLS, Gordon was a Partner with Cooley LLP, one of the leading biotechnology and technology law firms. Before joining Cooley LLP, Gordon was Executive Vice President and General Counsel at Radiant Research. Early in his career, he served as an officer in the United States Navy, Judge Advocate General Corps. Gordon holds a J.D. from the University of California at Berkeley School of Law and graduated with High Honors in History, magna cum laude from Colgate University.

About Frazier Life Sciences:

Frazier Life Sciences invests globally in private and publicly traded companies that discover, develop, and commercialize innovative biopharmaceuticals. Frazier Life Sciences manages over $3.9 billion in capital, including Venture Funds focusing on company creation and private companies and the long-only Public Funds focused on small and mid-cap public companies. Since 2005, over 60 Frazier Life Sciences portfolio companies, many of which were created or seeded by FLS, have completed IPOs or M&As. The Frazier Life Sciences team consists of over 40 professionals in biopharmaceuticals, primarily located in Palo Alto, CA. (headquarters), San Diego, Seattle, Boston, New York, and London.

For more information about Frazier Life Sciences, please visit frazierls.com and follow us on LinkedIn.

For media inquiries, please contact:
Ailsa Dalgliesh, Ph. D.
Head of Investor Relations
ailsa@frazierls.com

PALO ALTO, Calif. – April 1, 2025 – Frazier Life Sciences (FLS), a longstanding investment firm focused on innovative therapeutics, today announced that Chris Aakre, Ph.D., is joining the FLS team as Principal of Company Creation. Dr. Aakre brings close to 10 years of providing strategic guidance in the life sciences space.

“We are thrilled to welcome Chris to Frazier Life Sciences,” said Patrick Heron, Managing Partner at FLS. “Chris’ science-driven approach and passion for shaping the strategic direction of innovative biotech companies will prove valuable as we continue to build and invest in transformative life science companies.”

Dr. Aakre brings deep expertise in program management, business development, and strategic execution in biopharma. His passion for collaborative problem-solving and translating scientific breakthroughs into real-world impact further strengthens FLS’ ability to build and advance biotech companies. As Principal of Company Creation, Dr. Aakre will help drive FLS’ company creation efforts and advance its mission of investing in and building pioneering life sciences companies.

“I have been highly impressed by Frazier Life Sciences’ strategic approach to navigating the complexities of life sciences investing,” said Dr. Aakre. “I am excited to continue working alongside this team in their efforts to build transformative companies that can drive real impact in patients’ lives.”

Prior to joining FLS, Dr. Aakre served as the Vice President at an FLS portfolio company, HilleVax, where he played a number of operational, business development, and program management roles. Before HilleVax, he was at Boston Consulting Group for five years, where he held multiple positions of growing responsibility to Principal, leading health care engagements across multiple functions (R&D, BD, Commercial) and therapeutic areas (oncology, vaccines, cell and gene therapy). Dr. Aakre earned his Ph.D. from the Massachusetts Institute of Technology (MIT).

About Frazier Life Sciences:

Frazier Life Sciences invests globally in private and publicly traded companies that discover, develop, and commercialize innovative biopharmaceuticals. Frazier Life Sciences manages over $3.9 billion in capital, including Venture Funds focusing on company creation and private companies and the long-only Public Funds focused on small and mid-cap public companies. Since 2005, over 60 Frazier Life Sciences portfolio companies, many of which were created or seeded by FLS, have completed IPOs or M&As. The Frazier Life Sciences team consists of over 40 professionals in biopharmaceuticals, primarily located in Palo Alto, Calif. (headquarters), San Diego, Seattle, Boston, New York, and London.

For more information about Frazier Life Sciences, please visit frazierls.com and follow us on LinkedIn.

Operating Professionals are employed by a subsidiary of FLS, provide advisory and consulting service to FLS and often serve in operational positions within FLS portfolio companies or search companies (“SearchCos”). Operating Professionals are permitted to receive a material equity position in a portfolio company or SearchCo, and any compensation paid to such Operating Professionals is borne directly or indirectly by the portfolio companies, SearchCos or the applicable FLS fund and will not offset any management fees.

For media inquiries, please contact:
Ailsa Dalgliesh, Ph. D.
Head of Investor Relations
ailsa@frazierls.com

PALO ALTO, Calif. – March 19, 2025 – Frazier Life Sciences (FLS), a longstanding investment firm focused on innovative therapeutics, today announced the promotion of Anna Chen, Ph.D., to Partner.

Dr. Chen joined FLS in 2018 and has played an integral role in the firm’s strategy, portfolio growth, and company creation efforts. Dr. Chen has led or co-led FLS’ investments in and currently serves on the boards of Alentis (a Series D FLS investment), Eyconis (an FLS Company Creation investment), and BlueWater Biosciences (another FLS Company Creation investment).

Dr. Chen has also played key roles in FLS investments such as Lengo Therapeutics, which was acquired by Blueprint Medicines for $250 million upfront in 2021, and SanReno Therapeutics, which Novartis acquired for an undisclosed amount in 2024. In addition, she was instrumental in FLS’ investments in Amunix Pharmaceuticals, which was acquired in 2021 by Sanofi for $1 billion upfront and up to $225 million upon achievement of certain development milestones.

“Anna has made many terrific investments, and we are excited to promote her to Partner,” said Patrick Heron, Managing Partner at FLS. “With her scientific acumen and ability to foster strong relationships with entrepreneurs, Anna has been pivotal to our team’s venture and company creation strategies.”

As Partner, Dr. Chen will continue sourcing cutting-edge technologies, structuring and negotiating complex transactions, and launching companies aimed at developing and delivering novel therapeutics.

“I am honored to join the partnership at Frazier Life Sciences and privileged to work within this exceptional team,” said Dr. Chen. “I look forward to continuing to build and support pioneering biotech companies that have the potential to bring life-changing treatments to patients.”

Prior to joining FLS, Dr. Chen was a management consultant at L.E.K. Consulting. Dr. Chen earned her Ph.D. in Systems Biology and her A.B. in Biochemical Sciences from Harvard University.

About Frazier Life Sciences:

Frazier Life Sciences invests globally in private and publicly traded companies that discover, develop, and commercialize innovative biopharmaceuticals. Frazier LifeSciences manages over $3.9 billion in capital, including Venture Funds focusing on company creation and private companies and the long-only Public Funds focused on small and mid-cap public companies. Since 2005, over 60 Frazier Life Sciences portfolio companies, many of which were created or seeded by FLS, have completed IPOs or M&As. The Frazier Life Sciences team consists of over 40 professionals in biopharmaceuticals, primarily located in Palo Alto, Calif. (headquarters), San Diego, Seattle, Boston, New York, and London.

For more information about Frazier Life Sciences, please visit frazierls.com and follow us on LinkedIn.

For media inquiries, please contact:
Ailsa Dalgliesh, Ph. D.
Head of Investor Relations
ailsa@frazierls.com

PALO ALTO, Calif. – March 6, 2025 – Frazier Life Sciences (FLS), a longstanding investment firm focused on innovative therapeutics, today announced the appointment of Gerald (Jerry) Nepom, M.D., Ph.D., as Senior Advisor.

Dr. Nepom has over four decades of biomedical experience in clinical and translational immunology, with extensive knowledge spanning autoimmune diseases, allergy, and transplantation. He founded the Benaroya Research Institute (BRI), the first translational immunology institute in the U.S., where he served as Director from 1985 to 2015, leading research on T-cell function and immune regulation in diseases such as type 1 diabetes, lupus, and rheumatoid arthritis. From 2010 to 2023, he directed the Immune Tolerance Network (ITN), overseeing National Institutes of Health-sponsored clinical trials aimed at advancing novel immunomodulatory therapies.

“Jerry has played a pivotal role in translating immunological insights into clinical applications, and his broad experience in both academia and industry will be beneficial to our team,” said Jamie Topper, Managing Partner at FLS. “His ability to bridge scientific discovery with biotech innovation strongly aligns with our commitment to advancing potentially transformative therapies through new and innovative companies.”

In addition to his leadership at BRI and ITN, Dr. Nepom has advised numerous biotechnology and pharmaceutical companies, serving on advisory boards for both early-stage startups and global pharmaceutical companies such as Pfizer. He has also been a key figure in shaping national research priorities, having chaired the National Institutes of Health’s first strategic planning committee for autoimmune diseases and contributed to over 200 clinical programs.

“I have been impressed by the depth of experience and thoughtful approach at Frazier Life Sciences in working to make a meaningful impact in biotechnology,” said Dr. Nepom. “I look forward to contributing my experience in immunology and clinical development to support their mission.”

Dr. Nepom earned his A.B. from Harvard University and both his M.D. and Ph.D. from the University of Washington School of Medicine. He has received several accolades, including the University of Washington School of Medicine Distinguished Alumni Award and the David Rumbough Award for Scientific Excellence from the Juvenile Diabetes Research Foundation.

About Frazier Life Sciences:

Frazier Life Sciences invests globally in private and publicly traded companies that discover, develop, and commercialize innovative biopharmaceuticals. Frazier Life Sciences manages over $3.9 billion in capital, including Venture Funds focusing oncompany creation and private companies and the long-only Public Funds focused on small and mid-cap public companies. Since 2005, over 60 Frazier Life Sciences portfolio companies, many of which were created or seeded by FLS, have completed IPOs or M&As. The Frazier Life Sciences team consists of over 40 professionals in biopharmaceuticals, primarily located in Palo Alto, Calif. (headquarters), San Diego, Seattle, Boston, New York and London.

For more information about Frazier Life Sciences, please visit frazierls.com and follow us on LinkedIn.

For media inquiries, please contact:
Ailsa Dalgliesh, Ph. D.
Head of Investor Relations
ailsa@frazierls.com